Brokerages Set MiNK Therapeutics, Inc. (NASDAQ:INKT) Target Price at $37.50

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) have earned a consensus rating of “Moderate Buy” from the five analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $37.50.

A number of research firms have recently weighed in on INKT. Wall Street Zen lowered shares of MiNK Therapeutics to a “strong sell” rating in a research note on Saturday, August 23rd. B. Riley raised shares of MiNK Therapeutics to a “strong-buy” rating in a research note on Friday, July 18th. Zacks Research downgraded shares of MiNK Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, August 18th. HC Wainwright raised shares of MiNK Therapeutics from a “neutral” rating to a “buy” rating and set a $35.00 price target on the stock in a research note on Friday, August 15th. Finally, William Blair downgraded shares of MiNK Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Friday, July 11th.

MiNK Therapeutics Trading Down 1.7%

Shares of MiNK Therapeutics stock opened at $15.09 on Wednesday. MiNK Therapeutics has a 12-month low of $4.56 and a 12-month high of $76.00. The firm has a market capitalization of $68.21 million, a price-to-earnings ratio of -5.24 and a beta of 0.33. The firm’s 50 day simple moving average is $16.47 and its two-hundred day simple moving average is $11.10.

MiNK Therapeutics (NASDAQ:INKT) last released its quarterly earnings data on Thursday, August 14th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.51). On average, sell-side analysts predict that MiNK Therapeutics will post -2.75 EPS for the current fiscal year.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.